Publication at Third Faculty of Medicine |
2011
Abstract
BIBF 1120 is a novel oral anti-angiogenic agent intended for the therapy of non-small cell lung cancer. Its most notable characteristic is its ability to inhibit three relevant receptors, VEGF, PDGF, and FGF.
Particularly highlighted is its rapid onset of inhibition as well as the duration of the inhibition so that it is possible to infer long-lasting anti- -angiogenic effects. BIBF 1120 has linear pharmacokinetics, large distribution volume, and its biological elimination half-life is 19 hours.
Two large randomised phase III clinical trials, LUME-Lung 1 a 2, are ongoing. Both are investigating whether the addition of BIBF 1120 to standard chemotherapy will improve clinical outcomes as second-line treatment of patients with advanced NSCLC.